Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» immuno-oncology
immuno-oncology
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Fri, 04/6/18 - 11:49 am
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Novartis, Harvard team up to develop immunotherapy drug-delivery systems
Drug Delivery Business News
Thu, 03/22/18 - 09:03 am
Novartis
Harvard
immunotherapy
drug delivery
R&D
immuno-oncology
Bristol losing its I/O talent to the likes of Pfizer, report finds
Biopharma Dive
Sat, 02/24/18 - 10:39 pm
Bristol-Myers Squibb
Pfizer
Celgene
immuno-oncology
R&D
JPM18: Regeneron, Sanofi boost I/O investment
Biopharma Dive
Mon, 01/8/18 - 10:02 pm
Regeneron
Sanofi
immuno-oncology
JPMHC 2018
Advancing Immuno-Oncology: The CytomX Story
PharmExec
Thu, 01/4/18 - 11:22 am
CytomX
immuno-oncology
Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins
Endpoints
Tue, 01/2/18 - 11:28 am
Celgene
immuno-oncology
NexImmune
Johns Hopkins
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
Fri, 12/22/17 - 09:46 am
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Endpoints
Thu, 12/14/17 - 11:16 am
Bristol-Myers Squibb
Opdivo
Ono Pharmaceutical
ONO-4578
immuno-oncology
drug development
There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?
Endpoints
Thu, 12/7/17 - 09:24 am
cancer
immuno-oncology
drug development
R&D
Recent Developments for Merck’s Keytruda
Market Realist
Fri, 12/1/17 - 12:02 pm
Merck
Keytruda
immuno-oncology
anti-PD-1 immunotherapy
non-small cell lung cancer
Argos finds silver lining for I/O candidate
BioPharma Dive
Tue, 11/14/17 - 07:55 pm
Argos
immuno-oncology
rocapuldencel-T
AstraZeneca executives try to shift I-O focus with China, Brilinta wins
Fierce Pharma
Fri, 11/10/17 - 09:35 am
AstraZeneca
immuno-oncology
China
Brilinta
Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
BioPharma Dive
Sun, 09/17/17 - 09:54 am
M&A
immuno-oncology
biosimilars
Cancer patients know immuno-oncology and top drugs, but lack details: study
Fierce Pharma
Wed, 09/13/17 - 11:07 am
patients
cancer
immuno-oncology
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Fri, 08/18/17 - 12:01 am
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
AstraZeneca fights back in cancer with new hires, fast drug status
Yahoo/Reuters
Mon, 07/31/17 - 09:56 am
AstraZeneca
Imfinzi
immuno-oncology
Bristol shrugs off comparisons to MYSTIC
BioPharma Dive
Fri, 07/28/17 - 11:38 am
AstraZeneca
Bristol-Myers Squibb
Mystic
immuno-oncology
Opdivo
A humbling setback for an immune-revving cancer therapy underscores the many questions facing the field
Stat
Thu, 07/27/17 - 07:44 pm
AstraZeneca
Mystic
immuno-oncology
AstraZeneca lung cancer immunotherapy trial failure sends shares plunging
Stat
Thu, 07/27/17 - 09:59 am
AstraZeneca
Mystic
immuno-oncology
clinical trials
tremelimumab
Imfinzi
FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
RAPS.org
Wed, 07/12/17 - 02:41 pm
FDA
labeling
Keytruda
Opdivo
Yervoy
immuno-oncology
Merck
Bristol-Myers Squibb
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
next ›
last »